The Pirbright Institute is partnering with Scitech, a leading specialist in pharmaceutical design, engineering, construction and qualification, to build and deliver a new Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM).
CVIM’s mission is to fulfil an unmet global need to accelerate the development and production of novel vaccines that can be produced at scale, cost-effectively, and formulated for mass deployment.
Equipped with bespoke facilities and leading-edge research expertise, CVIM will target neglected and emerging diseases of livestock, including zoonotic diseases that represent a threat to public health.
Professor Bryan Charleston, director of the Pirbright Institute, said: “Scitech brings together expertise in design and engineering, construction and commissioning to deliver on our mission to translate scientific discoveries into solutions for the most challenging, emerging, and urgent infectious diseases.”
CVIM will be a single-storey new build facility with laboratories, offices and roof-level plant room located on The Pirbright Institute’s site near Woking, Surrey. It will provide Good Manufacturing Practice (GMP) cleanrooms and support areas essential for developing and deploying animal vaccines.
Scitech Managing Director, Dave Grant, said: “We are delighted to have been successfully awarded the contract to construct and deliver CVIM, which will bridge the gap between basic research and late-stage product development.”
CVIM is supported by funding from the Bill & Melinda Gates Foundation, the Foreign Commonwealth Development Office and the UKRI Biotechnology and Biological Sciences Research Council (BBSRC).
Work is due to commence in early 2025.
For further information about CVIM, visit the webpage.
